GT Biopharma, Inc. — Director's Dealing 2021

Nov 12, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: GT Biopharma, Inc. (GTBP)
CIK: 0000109657
Period of Report: 2021-01-13

Reporting Person: Breen Michael Martin (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
10% Senior Convertible Debenture	$3.40		Common Stock ()		Direct
10% Senior Convertible Debenture	$3.40	2021-06-23	Common Stock ()		Direct

Footnotes

F1: Reflects a 10% Senior Convertible Debenture in the face amount of $100,000. While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the Debenture on the maturity date and the Debenture remained outstanding. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of $3.40 (which reflects the applicable conversion price on a post-reverse split basis).

F2: Reflects a 10% Senior Convertible Debenture in the face amount of $30,000. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of $3.40 (which reflects the applicable conversion price on a post-reverse split basis)